About World ADC Berlin
Access the Latest Antibody Drug Conjugate Industry Intelligence.
Antibody-drug conjugate drug development is not without significant challenges. As a community we’ve learned this the hard way. Earlier this year the Seattle Genetics SGN-CD33A reminded us how treacherous the path to a clinically impactful ADC can be.
However, following in the footsteps of Adcetris and Kadcyla, ADCs are entering an exciting new era. There are currently over 100 ADCs in preclinical development, 65 compounds in the clinic and 2 new market approvals anticipated for later this year.
Cleaner targets, optimized linker-drug chemistries, site specific conjugation and CMC improvements are all contributing to greater promise for patients.
2018 will mark the 8th year of World ADC Europe – the industry’s leading antibody drug conjugate conference. Each year over 300 members of the ADC community across 120 organisations converge at World ADC to share the latest science, data and lessons learned to develop more clinically effective ADCs.
“Clearly the leading forum in the field”
World ADC will give you the insight, tools and connections to propel your ADC research to clinical success.
Click below to be kept up to date with how the 2018 programme evolves